[go: up one dir, main page]

ATE482972T1 - Tgf-beta1-bindende und geträgerte peptide - Google Patents

Tgf-beta1-bindende und geträgerte peptide

Info

Publication number
ATE482972T1
ATE482972T1 AT04810432T AT04810432T ATE482972T1 AT E482972 T1 ATE482972 T1 AT E482972T1 AT 04810432 T AT04810432 T AT 04810432T AT 04810432 T AT04810432 T AT 04810432T AT E482972 T1 ATE482972 T1 AT E482972T1
Authority
AT
Austria
Prior art keywords
peptides
supported
tgf
preferred embodiments
supported peptides
Prior art date
Application number
AT04810432T
Other languages
English (en)
Inventor
Anthony Day
David A Estell
Christopher Murray
Scott Power
Beverly Turnquest
Original Assignee
Danisco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco Us Inc filed Critical Danisco Us Inc
Application granted granted Critical
Publication of ATE482972T1 publication Critical patent/ATE482972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT04810432T 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide ATE482972T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53118903P 2003-12-19 2003-12-19
US53095403P 2003-12-19 2003-12-19
US53120703P 2003-12-19 2003-12-19
PCT/US2004/036979 WO2005046710A2 (en) 2003-11-06 2004-11-06 Tgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
ATE482972T1 true ATE482972T1 (de) 2010-10-15

Family

ID=34596198

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692160B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE486087T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029812D1 (de)
DK (2) DK1692158T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005047314A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006246425B2 (en) * 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
JP4834554B2 (ja) * 2003-11-06 2011-12-14 ジェネンコー・インターナショナル・インク 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現
EP1692160B1 (de) * 2003-11-06 2010-10-27 Danisco US Inc. Fgf-5-bindende und geträgerte peptide
EP1800136B1 (de) * 2004-10-15 2011-12-07 Danisco US Inc. Kompetitven differential screening
DE602006016133D1 (de) 2005-06-10 2010-09-23 Medical Res Council London Verwendung von stefin a als gerüstprotein
EP1902066A4 (de) * 2005-07-13 2009-01-07 Amgen Mountain View Inc Il-6-bindende proteine
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
PL2061313T3 (pl) * 2006-09-16 2014-01-31 Soy Labs Llc Zastosowanie peptydu sojowego (lunazyny) do obniżania poziomu cholesterolu całkowitego i ldl
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
MX2009005734A (es) 2006-12-18 2009-06-10 Danisco Us Inc Genencor Div Mediadores de lacasa y metodos de uso.
KR20090101193A (ko) 2006-12-21 2009-09-24 다니스코 유에스 인크. 바실러스 종 １９５ 의 알파-아밀라아제 폴리펩티드에 대한 조성물 및 용도
US20100233780A1 (en) * 2007-06-06 2010-09-16 Wolfgang Aehle Methods for Improving Protein Properties
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
KR20100075985A (ko) * 2007-10-31 2010-07-05 다니스코 유에스 인크. 세린 프로테아제가 없는 배경에서의 중성 메탈로프로테아제의 제조 및 용도
CN101842479A (zh) * 2007-11-01 2010-09-22 丹尼斯科美国公司 用于改良宿主细胞内蛋白质生产的信号序列和共表达的分子伴侣
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
AU2008349567A1 (en) * 2008-01-29 2009-08-06 Danisco Us Inc. Expression of streptomyces subtilisin inhibitor (SSI) proteins in bacillus and streptomyces sp.
MX2010008359A (es) 2008-02-04 2010-08-30 Danisco Us Inc Variantes de alfa-amilasa ts23 con propiedades alteradas.
BRPI0823193A2 (pt) 2008-10-15 2019-09-24 Danisco Us Inc inibidores de protease de bowman birk variantes modificados
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
CN102341495A (zh) 2009-03-10 2012-02-01 丹尼斯科美国公司 巨大芽孢杆菌菌株DSM90相关的α-淀粉酶及其使用方法
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
WO2010117511A1 (en) 2009-04-08 2010-10-14 Danisco Us Inc. Halomonas strain wdg195-related alpha-amylases, and methods of use, thereof
US8530218B2 (en) * 2009-04-24 2013-09-10 Danisco Us Inc. Proteases with modified pro regions
BRPI1009982A2 (pt) * 2009-05-01 2017-06-27 Signal Investment & Man Co composição antimicrobiana hidratante
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
DK3190183T3 (da) 2009-12-09 2019-10-14 Danisco Us Inc Sammensætninger og fremgangsmåder omfattende proteasevarianter
EP2512501A4 (de) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen
US20120329993A1 (en) * 2009-12-30 2012-12-27 Legal Department Soy whey protein compositions and methods for recovering same
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
JP5833096B2 (ja) * 2010-03-31 2015-12-16 エイジェンシー フォー サイエンス， テクノロジー アンド リサーチＡｇｅｎｃｙ Ｆｏｒ Ｓｃｉｅｎｃｅ，Ｔｅｃｈｎｏｌｏｇｙ Ａｎｄ Ｒｅｓｅａｒｃｈ 両親媒性直鎖状ペプチド／ペプトイドおよびそれを含むヒドロゲル
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US20110281327A1 (en) 2010-04-15 2011-11-17 Danisco Us Inc. Compositions And Methods Comprising Variant Proteases
JP5813753B2 (ja) 2010-05-06 2015-11-17 ザ プロクター アンド ギャンブルカンパニー プロテアーゼ変異体を有する消費者製品
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
MX338925B (es) 2011-05-05 2016-05-06 Procter & Gamble Composiciones y metodos que comprenden variantes de proteasa serina.
RU2663114C2 (ru) 2011-05-05 2018-08-01 Дзе Проктер Энд Гэмбл Компани Способы и композиции, содержащие варианты сериновой протеазы
BR112014004444A2 (pt) 2011-08-31 2017-03-21 Danisco Us Inc composições e métodos que compreendem uma variante de enzima lipolítica
WO2013096653A1 (en) 2011-12-22 2013-06-27 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
MX361862B (es) 2012-10-12 2018-12-18 Danisco Us Inc Composiciones y métodos que comprenden variante de enzima lipolítica.
EP2914720B1 (de) 2012-11-05 2022-08-31 Danisco US Inc. Zusammensetzungen und verfahren mit thermolysinproteasevarianten
EP2935573A1 (de) 2012-12-19 2015-10-28 Danisco US Inc. Neuartige mannase, zusammensetzungen und verfahren zur verwendung davon
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
JP6367930B2 (ja) 2013-05-29 2018-08-01 ダニスコ・ユーエス・インク 新規メタロプロテアーゼ
CN105492603B (zh) 2013-05-29 2022-06-03 丹尼斯科美国公司 新型金属蛋白酶
EP3004341B1 (de) 2013-05-29 2017-08-30 Danisco US Inc. Neuartige metalloproteasen
US20160160202A1 (en) 2013-05-29 2016-06-09 Danisco Us Inc. Novel metalloproteases
EP3022299B1 (de) 2013-07-19 2020-03-18 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
US20160222368A1 (en) 2013-09-12 2016-08-04 Danisco Us Inc. Compositions and Methods Comprising LG12-CLADE Protease Variants
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
WO2015089447A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of the bacillus gibsonii-clade
ES2723948T3 (es) 2013-12-13 2019-09-04 Danisco Us Inc Serina proteasas procedentes de especies de Bacillus
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
MX2016012044A (es) 2014-03-21 2017-06-29 Danisco Us Inc Serina proteasas de especies de bacillus.
US20170233710A1 (en) 2014-10-17 2017-08-17 Danisco Us Inc. Serine proteases of bacillus species
DK3212662T3 (da) 2014-10-27 2020-07-20 Danisco Us Inc Serinproteaser
EP3212783B1 (de) 2014-10-27 2024-06-26 Danisco US Inc. Serinproteasen
WO2016069548A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3212782B1 (de) 2014-10-27 2019-04-17 Danisco US Inc. Serinproteasen
US20180010074A1 (en) 2014-10-27 2018-01-11 Danisco Us Inc. Serine proteases of bacillus species
EP3611259A1 (de) 2015-03-12 2020-02-19 Danisco US Inc. Zusammensetzungen und verfahren mit lg12-klade-proteasevarianten
JP7274819B2 (ja) 2015-05-13 2023-05-17 ダニスコ・ユーエス・インク ＡｐｒＬ－ＣＬＡＤＥプロテアーゼ変異体及びその使用
CN107922934A (zh) 2015-06-17 2018-04-17 丹尼斯科美国公司 具有经修饰的前肽区域的蛋白酶
US11499146B2 (en) 2015-06-17 2022-11-15 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
CN109072213A (zh) 2016-05-05 2018-12-21 丹尼斯科美国公司 蛋白酶变体及其用途
US11661567B2 (en) 2016-05-31 2023-05-30 Danisco Us Inc. Protease variants and uses thereof
WO2017219011A1 (en) 2016-06-17 2017-12-21 Danisco Us Inc Protease variants and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018118917A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
US20240279627A1 (en) 2018-08-30 2024-08-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
US12018262B2 (en) * 2018-10-31 2024-06-25 Qingdao Vland Biotech Group Co., Ltd Method for producing washing enzyme having protease resistance
EP3887515A1 (de) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
EP3976776A1 (de) 2019-05-24 2022-04-06 Danisco US Inc. Subtilisin-varianten und verwendungsverfahren
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
EP4090727A1 (de) 2020-01-13 2022-11-23 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
EP4204553A1 (de) 2020-08-27 2023-07-05 Danisco US Inc. Enzyme und enzymzusammensetzungen zur reinigung
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
US20240294888A1 (en) 2021-06-30 2024-09-05 Danisco Us Inc. Variant enzymes and uses thereof
US20240384205A1 (en) 2021-09-03 2024-11-21 Danisco Us Inc. Laundry compositions for cleaning
EP4448751A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
EP4448708A1 (de) 2021-12-16 2024-10-23 The Procter & Gamble Company Stoff- und heimpflegezusammensetzung mit einer protease
EP4448712A1 (de) 2021-12-16 2024-10-23 The Procter & Gamble Company Protease enthaltende zusammensetzung für geschirrspülmaschinen
CN118679252A (zh) 2021-12-16 2024-09-20 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
EP4448750A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verwendungen davon
EP4486858A1 (de) 2022-03-01 2025-01-08 Danisco US Inc. Enzyme und enzymzusammensetzungen zur reinigung
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use
WO2024163584A1 (en) 2023-02-01 2024-08-08 Danisco Us Inc. Subtilisin variants and methods of use
WO2024163695A1 (en) 2023-02-01 2024-08-08 The Procter & Gamble Company Detergent compositions containing enzymes
WO2024186819A1 (en) 2023-03-06 2024-09-12 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3929678A (en) * 1974-08-01 1975-12-30 Procter & Gamble Detergent composition having enhanced particulate soil removal performance
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
DK0794764T3 (da) 1994-11-28 1999-10-11 Procter & Gamble Topiske hudplejesammensætninger indeholdende fortykkede polyolcarboxylsyreestere som hudkonditionerende midler
AR001732A1 (es) 1996-03-12 1997-11-26 Genencor Int Celulasa alcalina novedosa y método para producirla
EP0991422A1 (de) * 1996-04-18 2000-04-12 The General Hospital Corporation Modulierende interaktionen des epitheliums und des mesenchyms
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2272306A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Cosmetic compositions
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
ATE223971T1 (de) * 1998-07-20 2002-09-15 Inoxell As Neue methoden zum auffinden von liganden- und ziel-biomolekülen
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
PT1360500E (pt) * 2000-04-14 2010-04-19 Genencor Int Métodos para direccionamento selectivo
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
AU2001271589A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
US6537968B1 (en) 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
EP2105503B1 (de) * 2000-12-13 2012-09-19 Anaphore, Inc. Verfahren zur Identifizierung und Isolierung von bindenden Polypeptiden aus kombinatorischen Bibliotheken von Proteinen mit der Gerüststruktur von lektinähnlichen Domänen vom C-Typ
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2002094867A2 (fr) * 2001-02-07 2002-11-28 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
WO2004072223A2 (en) * 2003-02-11 2004-08-26 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
JP4834554B2 (ja) * 2003-11-06 2011-12-14 ジェネンコー・インターナショナル・インク 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現
EP1692160B1 (de) * 2003-11-06 2010-10-27 Danisco US Inc. Fgf-5-bindende und geträgerte peptide
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

Also Published As

Publication number Publication date
US7413877B2 (en) 2008-08-19
JP5728329B2 (ja) 2015-06-03
EP1692158A2 (de) 2006-08-23
DK1680507T3 (da) 2011-10-10
US20080113917A1 (en) 2008-05-15
US20050203026A1 (en) 2005-09-15
WO2005046709A3 (en) 2005-11-24
US20050238607A1 (en) 2005-10-27
JP4843497B2 (ja) 2011-12-21
EP1692160B1 (de) 2010-10-27
ES2375360T3 (es) 2012-02-29
ATE486087T1 (de) 2010-11-15
EP1692159B1 (de) 2010-09-29
EP1692160A2 (de) 2006-08-23
US20090111160A1 (en) 2009-04-30
EP1692158B1 (de) 2011-10-26
DE602004029812D1 (de) 2010-12-09
US20080269139A1 (en) 2008-10-30
CA2544820C (en) 2014-02-18
EP1692159A2 (de) 2006-08-23
US7524816B2 (en) 2009-04-28
US7696173B2 (en) 2010-04-13
WO2005047511A2 (en) 2005-05-26
US20110230405A1 (en) 2011-09-22
WO2005046710A3 (en) 2005-11-24
WO2005046710A2 (en) 2005-05-26
ATE513917T1 (de) 2011-07-15
CA2544820A1 (en) 2005-05-26
US20050202535A1 (en) 2005-09-15
US7485618B2 (en) 2009-02-03
DE602004029393D1 (de) 2010-11-11
JP2012024091A (ja) 2012-02-09
US20130065829A1 (en) 2013-03-14
WO2005047314A3 (en) 2006-04-20
EP1680507A2 (de) 2006-07-19
WO2005047511A3 (en) 2005-11-24
DK1692158T3 (da) 2012-02-06
WO2005046709A2 (en) 2005-05-26
JP2008500805A (ja) 2008-01-17
WO2005047314A2 (en) 2005-05-26
ATE530560T1 (de) 2011-11-15
EP1680507B1 (de) 2011-06-22

Similar Documents

Publication Publication Date Title
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE602004011770D1 (de) Fusionsproteine
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DK1534830T3 (da) In vito-peptid-ekspressionsbibliotek
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE363531T1 (de) Claudin polypeptide
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties